PofoliaShared via Pofolia

Neuropsychobiology· 2013Q1· Review

Translational Findings on Brain-Derived Neurotrophic Factor and Anxiety: Contributions from Basic Research to Clinical Practice

Anna Claudia Domingos da Silveira da Luz, Gisele Pereira Dias, Mário Cesar do Nascimento Bevilaqua, Graham Cocks et al.

Short summary

The BDNF Val(66)Met polymorphism is linked to anxiety disorders, with animal studies showing reduced BDNF secretion in specific genotypes correlating with anxiety.

AI-generated from the title and abstract; the full text is not read.

Key points

  • The BDNF Val(66)Met polymorphism is associated with anxiety disorders.
  • Animal studies demonstrate decreased BDNF secretion in Val/Met and Met/Met genotypes.
  • Reduced BDNF levels correlate with anatomical, behavioral, and physiological changes related to anxiety.
  • Translational models are crucial for understanding anxiety neurobiology and developing therapies.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND/AIMS: Anxious responses are evolutionarily adaptive, but excessive fear can become disabling and lead to anxiety disorders. Translational models of anxiety might be useful sources for understanding the neurobiology of fear and anxiety and can contribute to future proposals of therapeutic intervention for the disorders studied. Brain-derived neurotrophic factor (BDNF), which is known for its importance on neuroplasticity and contextual memory, has emerged as a relevant element for emotional memory. Recent studies show that the Val(66)Met BDNF polymorphism correlates with various psychiatric disorders, including anxiety, but there are several differences between experimental and clinical studies. METHODS: In this work, we review the literature focused on the BDNF Val(66)Met polymorphism and anxiety, and discuss biological findings from animal models to clinical studies. RESULTS: As occurs with other psychiatric disorders, anxiety correlates with anatomical, behavioral and physiological changes related to the BDNF polymorphism. In animal studies, it has been shown that a significant decrease in regulated secretion from both BDNFVal/Met and BDNFMet/Met neurons represented a significant decrease in available BDNF. CONCLUSION: These studies suggest that developing pharmacological strategies facilitating the release of BDNF from synapses or prolongation of the half-life of secreted BDNF may improve the therapeutic responses of humans expressing the BDNF polymorphism.

The authors' abstract, as published at the source. Neuropsychobiology, 2013 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Cellular and Molecular Neuroscience

Cellular and Molecular NeuroscienceNeuroscience